|Day Low/High||26.43 / 26.84|
|52 Wk Low/High||20.97 / 45.00|
-- Epinephrine Injection, USP Auto-Injector, 0.15 mg and 0.3 mg is Currently Available in Pharmacies across the United States --
Cramer says SolarCity is too hard for him and he's losing patience with Cigna.
With interest rate hikes this year a distinct possibility, the big money managers are springing into action, Cramer says. Here's what to buy.
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 2,335,857 share decrease in total short interest for Impax Laboratories Inc , to 3,238,440, a decrease of 41.90% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Impax (IPXL) reported lower-than-anticipated earnings and revenue for the 2016 second quarter and a downbeat forecast before Tuesday's market open.
The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.
The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 709,063 share increase in total short interest for Impax Laboratories Inc , to 6,260,150, an increase of 12.77% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
-- Experienced Executive Added to Advance Robust Generic Portfolio --
Australia's Mayne will shell out $652 million for a basket of generics products from Teva as the latter works to complete its pending Allergan generics purchase.
Trade-Ideas LLC identified Impax Laboratories (IPXL) as a "dead cat bounce" (down big yesterday but up big today) candidate
The deal helps the Israeli drug giant comply with required antitrust divestitures connected to completion of its $40.5 billion acquisition of the generics business of Allergan.
Impax Laboratories (IPXL) stock is plunging after the company agreed to buy a portfolio of generic drugs from Teva Pharmaceuticals (TEVA) and Allergan (AGN) for $586 million.
Trade-Ideas LLC identified Impax Laboratories (IPXL) as a weak on high relative volume candidate
- Transaction Expected to Enhance Earnings Growth Potential -
EMVERM Provides a New Option for Patients with Pinworm, Whipworm, Roundworm and Hookworm in Single or Mixed Infections
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CAG, CCBG, CREE, ESRT, MLNX, MPX, PDCO, TMUS, VSAT, WMT Downgrades: BKU, FFIN, INSY, IPXL, LM, MGLN, MRC, THC Initiations: ONDK, VLRS Read on to get TheStreet Quant Ratings' detailed report:
Impax Laboratories (IPXL) stock is declining on Monday after posting its 2015 fourth quarter results before today’s opening bell.